Single Cell Sequencing and Multidimensional Omics Studies in Cardiovascular and Neurological Diseases
NCT ID: NCT06114095
Last Updated: 2023-11-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
400 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-04-01
Study Completion Date
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Research purpose Using single-cell sequencing, 3D/4D genomics and multidimensional omics technologies to reveal the complex cellular and molecular regulatory networks of cardiovascular and nervous system diseases, unique phenotypic changes of specific cell types, and different gene expression patterns, identify cell types and cell subsets associated with cardiovascular and nervous system diseases, and discover disease-related genes. To reveal new pathological mechanisms of related diseases and develop new diagnosis and treatment methods.
Research background Cardiovascular and nervous system diseases such as arrhythmias (atrial fibrillation, ventricular tachycardia, ventricular fibrillation, postoperative vascular stenosis injury, etc.), heart failure, atherosclerosis (coronary heart disease, stroke, peripheral vascular disease, carotid atherosclerosis, etc.), epilepsy, moyamoya disease, etc., are currently leading to the main diseases affecting the health and death of residents in China.
The data integration method based on single-cell sequencing, multi-omics data, and machine learning to analyze molecular level changes in cardiovascular and nervous system-related diseases can help deepen the research on the pathogenesis of cardiovascular and nervous system-related diseases and provide new ideas for the prevention and treatment of related diseases.
Research background Cardiovascular and nervous system diseases such as arrhythmias (atrial fibrillation, ventricular tachycardia, ventricular fibrillation, postoperative vascular stenosis injury, etc.), heart failure, atherosclerosis (coronary heart disease, stroke, peripheral vascular disease, carotid atherosclerosis, etc.), epilepsy, moyamoya disease, etc., are currently leading to the main diseases affecting the health and death of residents in China.
The data integration method based on single-cell sequencing, multi-omics data, and machine learning to analyze molecular level changes in cardiovascular and nervous system-related diseases can help deepen the research on the pathogenesis of cardiovascular and nervous system-related diseases and provide new ideas for the prevention and treatment of related diseases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association Analysis of Cardiovascular and Nervous System Diseases and Intestinal Microbiome Based on Multi-omics Big Data and Related Applications
NCT06099496
Nervous System Diseases
Cardiovascular and Cerebrovascular Diseases
RECRUITING
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
NCT05638269
Essential Hypertension
Liver Cancer
Nasopharyngeal Cancer
+8 more
RECRUITING
Dynamic Monitoring of Circulating microRNA Changes in Patients With or Without Multiple Organ Failure
NCT03059524
Multiple Organ Failure
UNKNOWN
Large-scale Multi-omics Analysis of Cerebrospinal Fluid
NCT06636201
Aging
RECRUITING
Multi-omics Database Construction of Healthy Korean Volunteers
NCT06183697
Healthy
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Test population Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease) and corresponding control cohort of normal tissue.
2. Sample size calculation Through literature research and clinical diagnosis experience, reliable conclusions can be obtained with an experimental cohort of 200 or more people and a control cohort. So the experimental data were selected from a disease cohort of 200 people and a control cohort of 200 people.
3. Specific research content
<!-- -->
1. Clinical data collection Clinical data (name, age, sex, weight/height ratio (BMI), three routine procedures (blood routine, stool routine, urine routine), blood biochemistry, liver and kidney function, coagulation function, bedside electrocardiogram, 24-hour holter electrocardiogram, heart color Doppler ultrasound, carotid color Doppler ultrasound, family history, past history, medication history, treatment history, and personal history) were collected from patients who met the inclusion criteria and controls Etc.), sign a written informed consent.
1. Blood collection: Collect 5-10ml of fasting blood from the experimental population in the morning for blood routine, blood biochemistry, liver and kidney function, coagulation function and other tests.
2. Fecal collection: 3-5g feces of the experimental population without eating from 6 a.m. to 9 a.m. will be collected for stool routine and intestinal flora detection. Note: The sample must not take antibiotics and other drugs within 45 days.
3. Urine collection: Collect the first urine of the experimental group in the morning, and reserve 10-12ml of fresh midstream urine for routine urine detection.
After testing the samples collected above, the test results were put into the corresponding experimental population data.
2. Single cell sequencing
1. Sample collection and processing ① Sample collection:
Sample collection of patients with atrial fibrillation:
A small amount of useless left atrial appendage tissue 100mg was taken as a sample during surgical treatment of atrial fibrillation patients. (The tissue used in this study was either residual tissue or abandoned tissue, and both were necessary for surgical resection, so there was no additional risk to the subjects)
Atrial fibrillation control heart tissue sample collection:
Atrial fibrillation control heart tissue was 100mg of cut waste tissue from heart transplant donor heart.
Carotid atherosclerosis sample collection:
During the surgical treatment of carotid atherosclerotic plaque endarterectomy, at least 1mg of the central tissue of discarded vascular plaque was collected as a sample.
Carotid atherosclerosis control sample collection:
During the surgical treatment of carotid atherosclerotic plaque endarterectomy, at least 1mg of marginal tissue of discarded vascular plaque was collected as control samples.
Moyamoya disease sample collection:
During cerebrovascular bypass surgery for Moyamoya disease, at least 1mg of discarded vascular tissue was collected as a sample.
Moyamoya disease control sample collection:
During cerebrovascular bypass surgery in non-moyamoya disease patients, at least 1mg of pruned waste vascular tissue was collected as a sample.
* Sample preservation and delivery: Considering that on-site experiments need to be booked in advance and coordinated, and there are many uncertain factors in clinical sample collection. For most freshly obtained samples, Miltenyi MACS Tissue Storage Solution® (130-100-008) is recommended. Optimized for the storage of fresh organ and tissue samples, the preservation solution has been tested and validated on a variety of human and mouse tissues, including tumors, skin, heart, spleen, brain, and skeletal muscle.
Procedure for using the preservation solution: a) Collect fresh samples from the operating room or anatomy, and quickly remove non-target tissues such as fat, hair, fibers, necrotic parts, etc., within 10 minutes; b) If the tissue block is large, it is recommended to divide it into soybean size and save it or keep it for backup; c) Directly transfer the sample to the pre-cooled (2-8℃) tissue preservation solution (1.5ml EP tube) to ensure that the tissue blocks are completely covered and the sample name is well marked; d) Seal the sample tube with sealing film, separate the sample from the ice pack with foam paper, put it in a ziplock bag, and arrange the ice pack to be sent as soon as possible. a) The tissue storage solution can be stored for 48h. In order to ensure the quality of the sample, the logistics delivery should be delivered the next day or the next morning, and the mailing should be delivered in advance of the sample date. b) It is recommended to place enough ice packs to avoid complete melting, and to avoid direct contact with the sample tube, causing the sample to freeze; c) Select a foam box with a thickness of not less than 3cm, and put some ice packs into the bottom first; d) The sample tube and the ice pack should be separated by foam paper or bubble bag; It is necessary to prepare the ice pack in advance, and avoid taking the ice bag out directly from -80℃ and -20℃, otherwise the tissue block will freeze due to low temperature, resulting in tissue damage.
③ Digestion: Fresh heart tissue (no less than 100mg of control clipped tissue, 3-4 pieces of puncture tissue (16G puncture needle, 1.5cm)), chopped into 1\~3mm3 tissue blocks, And transferred to 15 ml EP tubes of DMEM containing collagenase I (450 U ML-1), DNase I (60 U ML-1) and hyaluronidase (60 U ML-1). Incubate at 37 ° C for 1 hour, then add HBB buffer (2% FBS and 0.2% BSA in HBSS) to stop digestion, filter through a 40 µm filter into a 50 ml conical tube, transfer to a clean 15 ml EP tube and centrifuge at 4 ° C 350g for 5 min. The supernatant was then removed and the particles were re-suspended in 1 ml of ACK lysis buffer (Gibco, A10492), digested at room temperature for 5 minutes before 9 ml of DMEM was added. The supernatant was removed by centrifugation and re-suspended in 5 ml FACS buffer (2% FBS and 2mM EDTA, in a calcium/magnesium free PBS).
④ Sorting: Centrifugation was repeated under the above conditions, the supernatant was removed, and the cell particles were re-suspended in 300 µl cell suspension buffer (0.04%BSA, 1×PBS) and 1 µl DRAQ5 (Thermo Fisher Scientific, 62251) and 4, 6-diaminidine - 2-phenylindole (DAPI; BD Biosciences, 564907) and incubate for 5 minutes before sorting. DRAQ5+/DAPI- cells are collected in a cell re-suspension buffer. The collected cells were then re-centrifuged according to the above parameters and re-suspended in a cell re-suspension buffer to a target concentration of 1,000 cells ul-1. The cells are counted with a blood cell counter and the concentration is adjusted as needed.
⑤ Database building: All reagents required for database building are included in 10X Genomics Single Cell 3 'Reagent Kits v2 kit or BD database building kit.
2. Sample size calculation Through literature research and clinical diagnosis experience, reliable conclusions can be obtained with an experimental cohort of 200 or more people and a control cohort. So the experimental data were selected from a disease cohort of 200 people and a control cohort of 200 people.
3. Specific research content
<!-- -->
1. Clinical data collection Clinical data (name, age, sex, weight/height ratio (BMI), three routine procedures (blood routine, stool routine, urine routine), blood biochemistry, liver and kidney function, coagulation function, bedside electrocardiogram, 24-hour holter electrocardiogram, heart color Doppler ultrasound, carotid color Doppler ultrasound, family history, past history, medication history, treatment history, and personal history) were collected from patients who met the inclusion criteria and controls Etc.), sign a written informed consent.
1. Blood collection: Collect 5-10ml of fasting blood from the experimental population in the morning for blood routine, blood biochemistry, liver and kidney function, coagulation function and other tests.
2. Fecal collection: 3-5g feces of the experimental population without eating from 6 a.m. to 9 a.m. will be collected for stool routine and intestinal flora detection. Note: The sample must not take antibiotics and other drugs within 45 days.
3. Urine collection: Collect the first urine of the experimental group in the morning, and reserve 10-12ml of fresh midstream urine for routine urine detection.
After testing the samples collected above, the test results were put into the corresponding experimental population data.
2. Single cell sequencing
1. Sample collection and processing ① Sample collection:
Sample collection of patients with atrial fibrillation:
A small amount of useless left atrial appendage tissue 100mg was taken as a sample during surgical treatment of atrial fibrillation patients. (The tissue used in this study was either residual tissue or abandoned tissue, and both were necessary for surgical resection, so there was no additional risk to the subjects)
Atrial fibrillation control heart tissue sample collection:
Atrial fibrillation control heart tissue was 100mg of cut waste tissue from heart transplant donor heart.
Carotid atherosclerosis sample collection:
During the surgical treatment of carotid atherosclerotic plaque endarterectomy, at least 1mg of the central tissue of discarded vascular plaque was collected as a sample.
Carotid atherosclerosis control sample collection:
During the surgical treatment of carotid atherosclerotic plaque endarterectomy, at least 1mg of marginal tissue of discarded vascular plaque was collected as control samples.
Moyamoya disease sample collection:
During cerebrovascular bypass surgery for Moyamoya disease, at least 1mg of discarded vascular tissue was collected as a sample.
Moyamoya disease control sample collection:
During cerebrovascular bypass surgery in non-moyamoya disease patients, at least 1mg of pruned waste vascular tissue was collected as a sample.
* Sample preservation and delivery: Considering that on-site experiments need to be booked in advance and coordinated, and there are many uncertain factors in clinical sample collection. For most freshly obtained samples, Miltenyi MACS Tissue Storage Solution® (130-100-008) is recommended. Optimized for the storage of fresh organ and tissue samples, the preservation solution has been tested and validated on a variety of human and mouse tissues, including tumors, skin, heart, spleen, brain, and skeletal muscle.
Procedure for using the preservation solution: a) Collect fresh samples from the operating room or anatomy, and quickly remove non-target tissues such as fat, hair, fibers, necrotic parts, etc., within 10 minutes; b) If the tissue block is large, it is recommended to divide it into soybean size and save it or keep it for backup; c) Directly transfer the sample to the pre-cooled (2-8℃) tissue preservation solution (1.5ml EP tube) to ensure that the tissue blocks are completely covered and the sample name is well marked; d) Seal the sample tube with sealing film, separate the sample from the ice pack with foam paper, put it in a ziplock bag, and arrange the ice pack to be sent as soon as possible. a) The tissue storage solution can be stored for 48h. In order to ensure the quality of the sample, the logistics delivery should be delivered the next day or the next morning, and the mailing should be delivered in advance of the sample date. b) It is recommended to place enough ice packs to avoid complete melting, and to avoid direct contact with the sample tube, causing the sample to freeze; c) Select a foam box with a thickness of not less than 3cm, and put some ice packs into the bottom first; d) The sample tube and the ice pack should be separated by foam paper or bubble bag; It is necessary to prepare the ice pack in advance, and avoid taking the ice bag out directly from -80℃ and -20℃, otherwise the tissue block will freeze due to low temperature, resulting in tissue damage.
③ Digestion: Fresh heart tissue (no less than 100mg of control clipped tissue, 3-4 pieces of puncture tissue (16G puncture needle, 1.5cm)), chopped into 1\~3mm3 tissue blocks, And transferred to 15 ml EP tubes of DMEM containing collagenase I (450 U ML-1), DNase I (60 U ML-1) and hyaluronidase (60 U ML-1). Incubate at 37 ° C for 1 hour, then add HBB buffer (2% FBS and 0.2% BSA in HBSS) to stop digestion, filter through a 40 µm filter into a 50 ml conical tube, transfer to a clean 15 ml EP tube and centrifuge at 4 ° C 350g for 5 min. The supernatant was then removed and the particles were re-suspended in 1 ml of ACK lysis buffer (Gibco, A10492), digested at room temperature for 5 minutes before 9 ml of DMEM was added. The supernatant was removed by centrifugation and re-suspended in 5 ml FACS buffer (2% FBS and 2mM EDTA, in a calcium/magnesium free PBS).
④ Sorting: Centrifugation was repeated under the above conditions, the supernatant was removed, and the cell particles were re-suspended in 300 µl cell suspension buffer (0.04%BSA, 1×PBS) and 1 µl DRAQ5 (Thermo Fisher Scientific, 62251) and 4, 6-diaminidine - 2-phenylindole (DAPI; BD Biosciences, 564907) and incubate for 5 minutes before sorting. DRAQ5+/DAPI- cells are collected in a cell re-suspension buffer. The collected cells were then re-centrifuged according to the above parameters and re-suspended in a cell re-suspension buffer to a target concentration of 1,000 cells ul-1. The cells are counted with a blood cell counter and the concentration is adjusted as needed.
⑤ Database building: All reagents required for database building are included in 10X Genomics Single Cell 3 'Reagent Kits v2 kit or BD database building kit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Nervous System Diseases
Cardiovascular Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Disease group
Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease)
No interventions assigned to this group
Healthy control group
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Moderate or above mitral valve disease; The occurrence of atrial fibrillation was recorded by 12-lead electrocardiogram or 24-hour holter electrocardiogram. 3.18≤ Age ≤75 years old.
No moderate or above mitral valve disease; No history of atrial fibrillation, 24-hour holter electrocardiogram did not record the occurrence of atrial fibrillation. 3.18≤ Age ≤75 years old.
Carotid atherosclerosis was confirmed by ultrasound, CTA and other imaging diagnosis. 2.18≤ Age ≤75 years old.
Imaging diagnosis confirmed moyamoya disease; 2.18≤ Age ≤75 years old.
Imaging diagnosis confirmed no moyamoya disease; 2.18≤ Age ≤75 years old.
No moderate or above mitral valve disease; No history of atrial fibrillation, 24-hour holter electrocardiogram did not record the occurrence of atrial fibrillation. 3.18≤ Age ≤75 years old.
Carotid atherosclerosis was confirmed by ultrasound, CTA and other imaging diagnosis. 2.18≤ Age ≤75 years old.
Imaging diagnosis confirmed moyamoya disease; 2.18≤ Age ≤75 years old.
Imaging diagnosis confirmed no moyamoya disease; 2.18≤ Age ≤75 years old.
Exclusion Criteria
Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure and other non-valvular factors cause atrial fibrillation.
Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure, etc.
History of carotid vascular surgery or trauma
No plaque margin tissue or marginal tissue injury was found in abandoned vessels in the same patient.
Previous history of cerebrovascular surgery or trauma.
Previous history of cerebrovascular surgery or trauma.
Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure, etc.
History of carotid vascular surgery or trauma
No plaque margin tissue or marginal tissue injury was found in abandoned vessels in the same patient.
Previous history of cerebrovascular surgery or trauma.
Previous history of cerebrovascular surgery or trauma.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tao Xin
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tao Xin
Director of Neurosurgery
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Tao
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. No abstract available.
Reference Type
BACKGROUND
Hu F, Zheng L, Liu S, Shen L, Liang E, Ding L, Wu L, Chen G, Fan X, Yao Y. Avoidance of Vagal Response During Circumferential Pulmonary Vein Isolation: Effect of Initiating Isolation From Right Anterior Ganglionated Plexi. Circ Arrhythm Electrophysiol. 2019 Dec;12(12):e007811. doi: 10.1161/CIRCEP.119.007811. Epub 2019 Nov 25.
Reference Type
BACKGROUND
Garnvik LE, Malmo V, Janszky I, Ellekjaer H, Wisloff U, Loennechen JP, Nes BM. Physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation: the HUNT study. Eur Heart J. 2020 Apr 14;41(15):1467-1475. doi: 10.1093/eurheartj/ehaa032.
Reference Type
BACKGROUND
Horn P, Bueltmann E, Buch CV, Schmiedek P. Arterio-embolic ischemic stroke in children with moyamoya disease. Childs Nerv Syst. 2005 Feb;21(2):104-7. doi: 10.1007/s00381-004-0962-y. Epub 2004 May 18.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YXLL-KY-2023(038)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
NCT07266051
NOT_YET_RECRUITING
Development and Validation of a Digital Twin-based Clinical Research System (X Town Stage I)
NCT06861283
RECRUITING
Gut Microbiota in Patients With Moyamoya Disease
NCT04890782
UNKNOWN
Brain Network Connectivity of Patients With Metabolic Diseases
NCT06725589
COMPLETED
Clinical Outcome in Patients With Syringomyelia（COPSM）
NCT04856839
UNKNOWN
Cardiovascular Structure and Function in the Mucopolysaccharidoses
NCT05063435
ACTIVE_NOT_RECRUITING
Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX
NCT07218653
NOT_YET_RECRUITING
EARLY_PHASE1
Symptom Clusters and Risk Factors of COVID-19 Patients
NCT05556707
COMPLETED
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
NCT06690593
RECRUITING
Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications
NCT02663362
RECRUITING
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
NCT04419870
RECRUITING
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
NCT06527326
RECRUITING
NA
CSF Single-cell Sequencing and Proteomics of Chronic Postsurgical Pain in Patients With Lower Limb Fractures
NCT06126289
UNKNOWN
Relationship Between Metabolic Profiles and Chronic Diseases and Neoplasms
NCT06524037
RECRUITING
A Multicenter Observational Cohort of Degenerative Spine Diseases in China（DSDC）
NCT05867732
COMPLETED
Spatially Transcriptomics Reveals Molecular Signatures in CRPS
NCT05986461
RECRUITING
Application of Biomarkers in Neurological Diseases
NCT05881226
RECRUITING
LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions
NCT05293366
RECRUITING
A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease
NCT06837272
RECRUITING
Mitochondrial Function in Circulating Cells and Muscle Tissue
NCT02700698
COMPLETED
Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study
NCT01068535
UNKNOWN
MRS to Determine Neuroinflammation and Oxidative Stress in MPS I
NCT03576729
COMPLETED
Transcriptomic Study of Adult Population With Marfan Syndrome
NCT05700175
RECRUITING
Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes
NCT03496961
UNKNOWN
NA
Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline
NCT00099567
COMPLETED